Peroxisome proliferator-activated receptor-gamma agonists inhibit the replication of respiratory syncytial virus (RSV) in human lung epithelial cells

Virology. 2006 Jul 5;350(2):335-46. doi: 10.1016/j.virol.2006.03.008. Epub 2006 Apr 17.


We have previously shown that peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists inhibited the inflammatory response of RSV-infected human lung epithelial cells. In this study, we supply evidence that specific PPARgamma agonists (15d-PGJ2, ciglitazone, troglitazone, Fmoc-Leu) efficiently blocked the RSV-induced cytotoxicity and development of syncytia in tissue culture (A549, HEp-2). All PPARgamma agonists under study markedly inhibited the cell surface expression of the viral G and F protein on RSV-infected A549 cells. This was paralleled by a reduced cellular amount of N protein-encoding mRNA determined by real-time RT-PCR. Concomitantly, a reduced release of infectious progeny virus into the cell supernatants of human lung epithelial cells (A549, normal human bronchial epithelial cells (NHBE)) was observed. Similar results were obtained regardless whether PPARgamma agonists were added prior to RSV infection or thereafter, suggesting that the agonists inhibited viral gene expression and not the primary adhesion or fusion process.

MeSH terms

  • Chromans / pharmacology
  • Humans
  • Lung / virology*
  • PPAR gamma / agonists*
  • Prostaglandin D2 / analogs & derivatives*
  • Prostaglandin D2 / pharmacology
  • Respiratory Mucosa / virology*
  • Respiratory Syncytial Viruses / drug effects
  • Respiratory Syncytial Viruses / physiology*
  • Thiazolidinediones / pharmacology
  • Troglitazone
  • Virus Replication / drug effects*
  • Virus Replication / physiology


  • 15-deoxyprostaglandin J2
  • Chromans
  • PPAR gamma
  • Thiazolidinediones
  • Troglitazone
  • Prostaglandin D2
  • ciglitazone